NNNN
Anbio Biotechnology
$17.22
-25.10%
$2.5B
No data for this timeframe.
Vol
Market Cap$2.5B
Cap SizeMid Cap
SEC Reports3
Exchange Nasdaq·Sector In Vitro & In Vivo Diagnostic Substances·Inc. E9·CIK 0001982708·Prev Close $22.99
Recent Activity
May 19, 2026
SEC
Anbio Biotechnology held an EGM on May 15, 2026, approving a share capital reduction, a massive increase in authorized s
6-K — Impact 4/10
Apr 27, 2026
SEC
Anbio Biotechnology filed proxy materials for a May 15, 2026 EGM seeking approval for a massive authorized share capital
6-K — Impact 7/10
Apr 7, 2026
SEC
Anbio Biotechnology's 20-F filing reveals strong financial growth with net income surging 170% YoY to $6.4M in 2025, dri
20-F — Impact 6/10
Mar 17, 2026
other
Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum
<p>FRANKFURT AM MAIN, Germany, March 17, 2026 (GLOBE NEWSWIRE) -- Anbio Biotechnology (NASDAQ: NNN
Latest Reports
NEUTRAL
6-K
4/10
Anbio Biotechnology held an EGM on May 15, 2026, approving a share capital reduction, a massive increase in authorized s
May 19, 2026
BEARISH
6-K
7/10
Anbio Biotechnology filed proxy materials for a May 15, 2026 EGM seeking approval for a massive authorized share capital
Apr 27, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 1 neutral. Avg impact: 5.7/10.
NEUTRAL
6-K
4/10
Anbio Biotechnology held an EGM on May 15, 2026, approving a share capital reduction, a massive incr
May 19, 2026
BEARISH
6-K
7/10
Anbio Biotechnology filed proxy materials for a May 15, 2026 EGM seeking approval for a massive auth
Apr 27, 2026
MIXED
20-F
6/10
Anbio Biotechnology's 20-F filing reveals strong financial growth with net income surging 170% YoY t
Apr 7, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Mar 17, 2026
other
Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum
<p>FRANKFURT AM MAIN, Germany, March 17, 2026 (GLOBE NEWSWIRE) -- Anbio Biotechnology (NASDAQ: NNNN) ("Anbio" or the "Company"), a global diagnostic